Stock AnalizAbbVie Inc. ABBV
Biotechnology: Pharmaceutical Preparations · IPO 2012 · data as of November 13, 2026
AbbVie Inc. (ABBV) is a healthcare company listed in the US with a market value of about $521.5B. In the twelve months to September 30, 2026 it had revenue of $66.0B and net income of $10.3B, a net margin of 15.7%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is shareholder returns (4/5); the weakest is value (0/5).
Key numbers: a P/E of 50.8, a price to free cash flow of 27.6, 5-year revenue growth of 6% a year, a 5-year average ROIC of 15%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 20% below the current price.
Score: 1.8 / 5
Checks passed
- Strong R&D investment or growth above 20%
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- Positive free cash flow
- Interest covered more than 5 times
- Pays a dividend
- 20% to 100% of free cash flow returned to shareholders
- Dividend 3 years in a row
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $66.0B | $61.2B | $56.3B | $54.3B | $58.1B | $56.2B | $45.8B | $33.3B | $32.8B | $28.2B | $25.6B |
| Net income | $10.3B | $4.2B | $4.3B | $4.9B | $11.8B | $11.5B | $4.6B | $7.9B | $5.7B | $5.3B | $6.0B |
| Free cash flow | $18.9B | $17.8B | $17.8B | $22.1B | $24.2B | $22.0B | $16.8B | $12.8B | $12.8B | $9.4B | $6.6B |
| EPS (diluted) | $5.81 | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 | $2.72 | $5.28 | $3.66 | $3.30 | $3.63 |
| Net margin | 15.7% | 6.9% | 7.6% | 8.9% | 20.4% | 20.5% | 10.1% | 23.7% | 17.4% | 18.8% | 23.2% |
| ROIC | — | 15.6% | 10.2% | 14.1% | 19.6% | 17.3% | 9.1% | 20.4% | 16.7% | 18.0% | 17.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 26 analysts is $311.81, 6% above the current price; targets range from $237.00 to $350.00; the consensus rating is “Buy”; expected EPS is $13.98 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is AbbVie’s P/E ratio?
About 50.8, based on the last twelve months of diluted earnings per share (forward P/E about 19.1).
Is AbbVie stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 20% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does AbbVie pay a dividend?
Yes. The dividend yield is about 2.35%, and it has paid dividends for 10 years in our data.
Is AbbVie a good stock to buy?
We do not give buy or sell advice. AbbVie scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.